Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 2/20 | 0.32 |
| ▸ | ADH1A | P07327 | 2/20 | 0.32 |
| ▸ | ADH7 | P40394 | 2/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16995359 | 0.82 | GNAI3 (0.39) | GNAI3GNAO1GNAI1CYP2C19ACE2 | |
| SCHEMBL12465584 | 0.81 | ACE2 (0.48) | ACE2CA12CA1CA2CA9 | |
| SCHEMBL14431493 | 0.81 | — | — | |
| SCHEMBL1785087 | 0.78 | GNAI3 (0.44) | GNAI3GNAO1GNAI1CYP2C19ACE2 | |
| SCHEMBL1307631 | 0.77 | CARM1 (0.50) | GNAI3GNAO1GNAI1ACE2ADH1B | |
| SCHEMBL5748707 | 0.77 | — | — | |
| SCHEMBL3947829 | 0.76 | ADH1B (0.50) | GNAI3GNAO1GNAI1CYP2C19ACE2 | |
| SCHEMBL19981892 | 0.75 | CARM1 (0.48) | GNAI3GNAO1GNAI1CA12CA1 | |
| SCHEMBL348039 | 0.75 | CARM1 (0.48) | GNAI3GNAO1GNAI1CA12CA1 | |
| SCHEMBL14673306 | 0.74 | ACE2 (0.42) | ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | GNAI3 1984/4885GNAO1 1201/4885GNAI1 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.